Keywords
LDL cholesterol
Cascade screening
Lipid-lowering therapy
Lomitapide
Evinacumab
How to Cite
Abstract
Introduction: Homozygous familial hypercholesterolemia (HoFH) is a rare but severe genetic disorder characterized by extremely elevated LDL-C levels from birth, leading to accelerated atherosclerosis and premature cardiovascular disease. Despite advances in lipid-lowering therapies, the evidence guiding clinical practice remains heterogeneous, highlighting the need for an expert consensus to synthesize available data and provide practical recommendations.
Objective: This narrative review aims to unify current medical evidence to guide the management of homozygous familial hypercholesterolemia (HoFH). Through a multidisciplinary expert consensus, the panel seeks to synthesize the available scientific information on HoFH. The main objective is to provide the medical community with practical, clear recommendations to optimize patient care, emphasizing three fundamental areas: improving the accuracy of early diagnosis, structuring comprehensive clinical management, and evaluating the effectiveness of emerging therapies. Ultimately, the panel's goal is to support actions to reduce the risk of premature cardiovascular disease, as well as to standardize the care of HoFH.
Methodology: This narrative review was developed through a multidisciplinary consensus process. Experts in internal medicine, cardiology, endocrinology, paediatrics, and medical genetics defined key topics, drafted sections according to their expertise, and iteratively refined the content through collaborative discussions. Evidence was selected pragmatically, based on clinical relevance and applicability, to inform diagnosis, management, and emerging therapies for HoFH.
Results: The review addresses major domains in the care of HoFH, including clinical and genetic diagnosis, differential diagnosis, cascade screening, cardiovascular risk assessment, and therapeutic approaches. Both non-pharmacological and pharmacological interventions are discussed, from statins and ezetimibe to lomitapide, evinacumab, and novel emerging therapies. Special populations such as paediatric patients and pregnant women are also considered. Additionally, the review highlights the social and public health impact of HoFH, emphasizing the importance of early detection and equitable access to advanced therapies.
Conclusions: HoFH is more prevalent than previously recognised and requires early diagnosis and comprehensive management. This consensus synthesizes expert experience and current evidence to provide practical guidance for clinicians. By integrating pharmacological, non-pharmacological, and genetic strategies, it aims to improve outcomes and reduce the cardiovascular burden of HoFH.
References
Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611-653. https://doi.org/10.1210/endrev/bnab037
Brown EE, Sturm AC, Cuchel M, Braun LT, Duell PB, Underberg JA, et al. Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. J Clin Lipidol. 2020;14(4):398-413. https://doi.org/10.1016/j.jacl.2020.04.011
Varghese MJ. Familial hypercholesterolemia: A review. Ann Pediatr Cardiol. 2014;7(2):107-117. https://doi.org/10.4103/0974-2069.132478
Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-2157. https://doi.org/10.1093/eurheartj/ehu274
Raal FJ, Bahassi EM, Stevens B, Turner TA, Stein EA. Cascade screening for familial hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020;40(11):2747-2755. https://doi.org/10.1161/ATVBAHA.120.315040
Abifadel M, Boileau C. Genetic and molecular architecture of familial hypercholesterolemia. J Intern Med. 2023;293(2):144-165. https://doi.org/10.1111/joim.13577
Rogozik J, G?ówczy?ska R, Grabowski M. Genetic backgrounds and diagnosis of familial hypercholesterolemia. Clin Genet. 2024;105(1):3-12. https://doi.org/10.1111/cge.14435
Tokgozoglu L, Kayikcioglu M. Familial hypercholesterolemia: Global burden and approaches. Curr Cardiol Rep. 2021;23(10):151. https://doi.org/10.1007/s11886-021-01565-5
Suryawanshi YN, Warbhe RA. Familial hypercholesterolemia: A literature review of the pathophysiology and current and novel treatments. Cureus. 2023;15(11):e49121. https://doi.org/10.7759/cureus.49121
Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553-2566. https://doi.org/10.1016/j.jacc.2020.03.057
Tada H, Kawashiri MA, Nohara A, Sekiya T, Watanabe A, Takamura M. Genetic counseling and genetic testing for familial hypercholesterolemia. Genes (Basel). 2024;15(3):297. https://doi.org/10.3390/genes15030297
Sawhney JPS, Prasad SR, Sharma M, Madan K, Mohanty A, Passey R, et al. Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India. Indian Heart J. 2019;71(2):118-122. https://doi.org/10.1016/j.ihj.2018.12.004
Harada-Shiba M, Ohtake A, Sugiyama D, Tada H, Dobashi K, Matsuki K, et al. Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022. J Atheroscler Thromb. 2023;30(5):531-557. https://doi.org/10.5551/jat.CR006
Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol. 2019;16(1):9-20. https://doi.org/10.1038/s41569-018-0052-6
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719-728. https://doi.org/10.1016/S0140-6736(21)02001-8
Mulder JWCM, Tromp TR, Al-Khnifsawi M, Blom DJ, Chlebus K, Cuchel M, et al. Sex differences in diagnosis, treatment, and cardiovascular outcomes in homozygous familial hypercholesterolemia. JAMA Cardiol. 2024;9(4):313-322. https://doi.org/10.1001/jamacardio.2023.5597
Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: New treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. https://doi.org/10.1093/eurheartj/ehad197
Fularski P, Hajdys J, Majchrowicz G, Stabrawa M, M?ynarska E, Rysz J, et al. Unveiling Familial hypercholesterolemia-review, cardiovascular complications, lipid-lowering treatment and its efficacy. Int J Mol Sci. 2024;25(3):1637. https://doi.org/10.3390/ijms25031637
Tada H. Personalized medicine beyond low-density lipoprotein cholesterol to combat residual risk for coronary artery disease. J Atheroscler Thromb. 2021;28(11):1130-1132. https://doi.org/10.5551/jat.ED162
Zubielien? K, Valteryt? G, Jonaitien? N, Žaliaduonyt? D, Zabiela V. Familial hypercholesterolemia and its current diagnostics and treatment possibilities: A literature analysis. Medicina (Kaunas). 2022;58(11):1665. https://doi.org/10.3390/medicina58111665
Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low density lipoprotein receptor to chromosome 19: Synteny of a receptor, a ligand, and a genetic disease. Proc Natl Acad Sci USA. 1984;81(9):2826-2830. https://doi.org/10.1073/pnas.81.9.2826
Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet. 2008;72(Pt 4):485-498. https://doi.org/10.1111/j.1469-1809.2008.00436.x
Brown MS, Goldstein JL. Analysis of a mutant strain of human fibroblasts with a defect in the internalization of receptor-bound low density lipoprotein. Cell. 1976;9(4 PT 2):663-674. https://doi.org/10.1016/0092-8674(76)90130-6
Brown MS, Goldstein JL. Familial hypercholesterolemia: Defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA. 1974;71(3):788-792. https://doi.org/10.1073/pnas.71.3.788
Brown MS, Goldstein JL. Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor. N Engl J Med. 1976;294(25):1386-1390. https://doi.org/10.1056/NEJM197606172942509
Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: Mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133-170. https://doi.org/10.1146/annurev.ge.24.120190.001025
Moorjani S, Roy M, Gagné C, Davignon J, Brun D, Toussaint M, et al. Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis. 1989;9(2):211-216. https://doi.org/10.1161/01.ATV.9.2.211
Law SW, Lackner KJ, Hospattankar AV, Anchors JM, Sakaguchi AY, Naylor SL, et al. Human apolipoprotein B-100: Cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. Proc Natl Acad Sci USA. 1985;82(24):8340-8344. https://doi.org/10.1073/pnas.82.24.8340
Weisgraber KH, Innerarity TL, Newhouse YM, Young SG, Arnold KS, Krauss RM, et al. Familial defective apolipoprotein B-100: Enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins. Proc Natl Acad Sci USA. 1988;85(24):9758-9762. https://doi.org/10.1073/pnas.85.24.9758
Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest. 1986;78(5):1410-1414. https://doi.org/10.1172/JCI112729
Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun. 2008;370(4):634-640. https://doi.org/10.1016/j.bbrc.2008.04.004
Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005;102(6):2069-2074. https://doi.org/10.1073/pnas.0409736102
Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-156. https://doi.org/10.1038/ng1161
Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292(5520):1394-1398. https://doi.org/10.1126/science.1060458
Mishra SK, Watkins SC, Traub LM. The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. Proc Natl Acad Sci USA. 2002;99(25):16099-16104. https://doi.org/10.1073/pnas.252630799
Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H, et al. Homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2021;28(7):665-678. https://doi.org/10.5551/jat.RV17050
Ruiz AJ, Patiño LF, Amaya K, Gómez JE, Ordóñez F, Paternina S, et al. Hipercolesterolemia familiar: serie de 36 casos con fenotipo de hipercolesterolemia familiar homocigótica. Rev Colomb Cardiol. 2020;27(6):498-507. https://doi.org/10.1016/j.rccar.2019.10.006
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. https://doi.org/10.1093/eurheartj/ehx144
Rocha VZ, Tada MT, Chacra APM, Miname MH, Mizuta MH. Update on sitosterolemia and atherosclerosis. Curr Atheroscler Rep. 2023;25(5):181-187. https://doi.org/10.1007/s11883-023-01092-4
Tada H, Nomura A, Ogura M, Ikewaki K, Ishigaki Y, Inagaki K, et al. Diagnosis and management of sitosterolemia 2021. J Atheroscler Thromb. 2021;28(8):791-801. https://doi.org/10.5551/jat.RV17052
Koyama S, Sekijima Y, Ogura M, Hori M, Matsuki K, Miida T, et al. Cerebrotendinous xanthomatosis: Molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments. J Atheroscler Thromb. 2021;28(9):905-925. https://doi.org/10.5551/jat.RV17055
Gómez-Duarte C, García V, Botero V, Aristizabal A, Echeverri G, Pachajoa H. Deficiencia de lipasa ácida lisosomal, una patología infrecuente. Gac Med Mex. 2019;155(3):291-297. https://doi.org/10.24875/GMM.18004024
Korbelius M, Kuentzel KB, Bradi? I, Vuji? N, Kratky D. Recent insights into lysosomal acid lipase deficiency. Trends Mol Med. 2023;29(6):425-438. https://doi.org/10.1016/j.molmed.2023.03.001
Jackson M, Marks L, May GHW, Wilson JB. The genetic basis of disease. Essays Biochem. 2018;62(5):643-723. https://doi.org/10.1042/EBC20170053
Lopes MT, Koch VH, Sarrubbi-Junior V, Gallo PR, Carneiro-Sampaio M. Difficulties in the diagnosis and treatment of rare diseases according to the perceptions of patients, relatives and health care professionals. Clinics (Sao Paulo). 2018;73:e68. https://doi.org/10.6061/clinics/2018/e68
Angural A, Spolia A, Mahajan A, Verma V, Sharma A, Kumar P, et al. Review: Understanding rare genetic diseases in low resource regions like Jammu and Kashmir - India. Front Genet. 2020;11:415. https://doi.org/10.3389/fgene.2020.00415
Grody WW. The transformation of medical genetics by clinical genomics: Hubris meets humility. Genet Med. 2019;21(9):1916-1926. https://doi.org/10.1038/s41436-019-0450-0
Katsanis SH, Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet. 2013;14(6):415-426. https://doi.org/10.1038/nrg3493
Smith HS, Swint JM, Lalani SR, Yamal JM, de Oliveira Otto MC, Castellanos S, et al. Clinical application of genome and exome sequencing as a diagnostic tool for pediatric patients: A scoping review of the literature. Genet Med. 2019;21(1):3-16. https://doi.org/10.1038/s41436-018-0024-6
Lalonde E, Rentas S, Lin F, Dulik MC, Skraban CM, Spinner NB. Genomic diagnosis for pediatric disorders: Revolution and evolution. Front Pediatr. 2020;8:373. https://doi.org/10.3389/fped.2020.00373
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57. https://doi.org/10.1093/nar/gnf056
Wang J, Ban MR, Hegele RA. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J Lipid Res. 2005;46(2):366-372. https://doi.org/10.1194/jlr.D400030-JLR200
Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018;72(6):662-680. https://doi.org/10.1016/j.jacc.2018.05.044
Lazarte J, Hegele RA. Can genetic testing help in the management of dyslipidaemias? Curr Opin Lipidol. 2020;31(4):187-193. https://doi.org/10.1097/MOL.0000000000000690
National Collaborating Centre for Primary Care (UK). Identification and management of familial hypercholesterolaemia (FH). London: National Institute for Health and Clinical Excellence; 2008.
National Institute for Health and Care Excellence (NICE). Familial hypercholesterolaemia: identification and management. NICE guideline [CG71]. London: NICE; 2019.
Srinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC. Barriers and facilitators for cascade testing in genetic conditions: A systematic review. Eur J Hum Genet. 2020;28(12):1631-1644. https://doi.org/10.1038/s41431-020-00725-5
Knowles JW, Rader DJ, Khoury MJ. Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA. 2017;318(4):381-382. https://doi.org/10.1001/jama.2017.8543
Lee C, Rivera-Valerio M, Bangash H, Prokop L, Kullo IJ. New case detection by cascade testing in familial hypercholesterolemia: A systematic review of the literature. Circ Genom Precis Med. 2019;12(11):e002723. https://doi.org/10.1161/CIRCGEN.119.002723
Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: A global call to action. JAMA Cardiol. 2020;5(2):217-229. https://doi.org/10.1001/jamacardio.2019.5173
Brunham LR, Ruel I, Aljenedil S, Rivière JB, Baass A, Tu JV, et al. Canadian cardiovascular society position statement on familial hypercholesterolemia: Update 2018. Can J Cardiol. 2018;34(12):1553-1563. https://doi.org/10.1016/j.cjca.2018.09.005
Paquette M, Dufour R, Baass A. The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):80-86. https://doi.org/10.1016/j.jacl.2016.10.004
Mata P, Alonso R, Pérez de Isla L. Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: Does one size fit all? Curr Opin Lipidol. 2018;29(6):445-452. https://doi.org/10.1097/MOL.0000000000000553
Tada H, Kawashiri MA, Okada H, Nakahashi T, Sakata K, Nohara A, et al. Assessments of carotid artery plaque burden in patients with familial hypercholesterolemia. Am J Cardiol. 2017;120(11):1955-1960. https://doi.org/10.1016/j.amjcard.2017.08.012
Bea AM, Civeira F, Jarauta E, Lamiquiz-Moneo I, Pérez-Calahorra S, Marco-Benedí V, et al. Association between the presence of carotid artery plaque and cardiovascular events in patients with genetic hypercholesterolemia. Rev Esp Cardiol (Engl Ed). 2017;70(7):551-558. https://doi.org/10.1016/j.recesp.2016.10.018
Mszar R, Nasir K, Santos RD. Coronary artery calcification in familial hypercholesterolemia: An opportunity for risk assessment and shared decision making with the power of zero? Circulation. 2020;142(15):1405-1407. https://doi.org/10.1161/CIRCULATIONAHA.120.049057
Gallo A, Pérez de Isla L, Charrière S, Vimont A, Alonso R, Muñiz-Grijalvo O, et al. The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia. JACC Cardiovasc Imaging. 2021;14(12):2414-2424. https://doi.org/10.1016/j.jcmg.2021.06.011
Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, Jiménez-Borreguero LJ, et al. Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: The AWHS study. J Am Coll Cardiol. 2016;67(11):1263-1274. https://doi.org/10.1016/j.jacc.2015.12.056
Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: A scientific statement from the American Heart Association. Circulation. 2015;132(22):2167-2192. https://doi.org/10.1161/CIR.0000000000000297
France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016;255:128-139. https://doi.org/10.1016/j.atherosclerosis.2016.10.017
Li R, Xie J, Jiang B, Sun Z, Wang L, Leng Z, et al. Speckle-tracking echocardiography for detecting subclinical left ventricular dysfunction in patients with familial hypercholesterolemia. Tex Heart Inst J. 2021;48(2):e186720. https://doi.org/10.14503/THIJ-18-6720
Sharifi M, Rakhit RD, Humphries SE, Nair D. Cardiovascular risk stratification in familial hypercholesterolaemia. Heart. 2016;102(13):1003-1008. https://doi.org/10.1136/heartjnl-2015-308845
Vuorio A, Raal FJ, Kovanen PT. Extension of heterozygous familial hypercholesterolemia treatment recommendations by including both low-density lipoprotein and lipoprotein(a) burden - a unique opportunity to improve patient prognosis. Eur J Prev Cardiol. 2025;32(9):780-782. https://doi.org/10.1093/eurjpc/zwae304
Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50-103. https://doi.org/10.1016/j.jacc.2010.09.001
Merchán A, Ruiz ÁJ, Campo R, Prada CE, Toro JM, Sánchez R, et al. Hipercolesterolemia familiar: artículo de revisión. Rev Colomb Cardiol. 2016;23(S4):4-26. https://doi.org/10.1016/j.rccar.2016.05.002
Alves AC, Alonso R, Diaz-Diaz JL, Medeiros AM, Jannes CE, Merchan A, et al. Phenotypical, clinical, and molecular aspects of adults and children with homozygous familial hypercholesterolemia in Iberoamerica. Arterioscler Thromb Vasc Biol. 2020;40(10):2508-2515. https://doi.org/10.1161/atvbaha.120.313722
Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, et al. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135(22):2133-2144. https://doi.org/10.1161/CIRCULATIONAHA.116.024541
Arsenault BJ, Perrot N, Couture P. Does lifestyle contribute to disease severity in patients with inherited lipid disorders? Curr Opin Lipidol. 2017;28(2):177-185. https://doi.org/10.1097/MOL.0000000000000387
Antoniazzi L. Can non-pharmacological treatment promote additional benefit for children with familial hypercholesterolemia treated with statins? Arq Bras Cardiol. 2018;111(6):822-823. https://doi.org/10.5935/abc.20180235
Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos DK, Randeva HS. Familial hypercholesterolemia: New horizons for diagnosis and effective management. Front Pharmacol. 2018;9:707. https://doi.org/10.3389/fphar.2018.00707
SEC Working Group for the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice and SEC Guidelines Committee. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed). 2022;75(5):364-369. https://doi.org/10.1016/j.rec.2021.10.023
Izar MCO, Giraldez VZR, Bertolami A, Santos Filho RDD, Lottenberg AM, Assad MHV, et al. Update of the Brazilian guideline for familial hypercholesterolemia - 2021. Arq Bras Cardiol. 2021;117(4):782-844. https://doi.org/10.36660/abc.20210788
Antoniazzi L, Arroyo-Olivares R, Bittencourt MS, Tada MT, Lima I, Jannes CE, et al. Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2021;31(7):2014-2022. https://doi.org/10.1016/j.numecd.2021.04.006
de Jongh S, Vissers MN, Rol P, Bakker HD, Kastelein JJ, Stroes ES. Plant sterols lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolaemia. J Inherit Metab Dis. 2003;26(4):343-351. https://doi.org/10.1023/A:1025155002348
Jenkins DJ, Jones PJ, Lamarche B, Kendall CW, Faulkner D, Cermakova L, et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: A randomized controlled trial. JAMA. 2011;306(8):831-839. https://doi.org/10.1001/jama.2011.1202
Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349-2358. https://doi.org/10.1056/NEJMoa1605086
Pitsavos CH, Chrysohoou C, Panagiotakos DB, Kokkinos P, Skoumas J, Papaioannou I, et al. Exercise capacity and heart rate recovery as predictors of coronary heart disease events, in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173(2):347-352. https://doi.org/10.1016/j.atherosclerosis.2003.12.027
SEC Working Group for the 2019 ESC/EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committee. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. Rev Esp Cardiol (Engl Ed). 2020;73(5):348-353. https://doi.org/10.1016/j.rec.2019.11.019
Nakamura T, Kobayashi H, Yanagi K, Nakagawa T, Nishida M, Kihara S, et al. Importance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. Int J Obes Relat Metab Disord. 1997;21(7):580-586. https://doi.org/10.1038/sj.ijo.0800445
Mangili LC, Mangili OC, Bittencourt MS, Miname MH, Harada PH, Lima LM, et al. Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia. Atherosclerosis. 2016;254:73-77. https://doi.org/10.1016/j.atherosclerosis.2016.09.010
Kramer A, Jansen AC, van Aalst-Cohen ES, Tanck MW, Kastelein JJ, Zwinderman AH. Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia. BMC Public Health. 2006;6:262. https://doi.org/10.1186/1471-2458-6-262
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-3490. https://doi.org/10.1093/eurheartj/eht273
Humphries SE, Cooper J, Dale P, Ramaswami U, Group FPRS. The UK Paediatric familial hypercholesterolaemia register: Statin-related safety and 1-year growth data. J Clin Lipidol. 2018;12(1):25-32. https://doi.org/10.1016/j.jacl.2017.11.005
Khoury M, McCrindle BW. The rationale, indications, safety, and use of statins in the pediatric population. Can J Cardiol. 2020;36(9):1372-1383. https://doi.org/10.1016/j.cjca.2020.03.041
Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):1547-1556. https://doi.org/10.1056/NEJMoa1816454
Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014;312(10):1055-1057. https://doi.org/10.1001/jama.2014.8892
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082-e1143. https://doi.org/10.1161/CIR.0000000000000698
Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. Endocr Pract. 2020;26(10):1196-1224. https://doi.org/10.4158/CS-2020-0490
Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: A systematic evidence review for the U.S. preventive services task force. 2016;316(6)645-655. https://doi.org/10.1001/jama.2016.6176
Peaker B, Dideum P, Arkhipova-Jenkins I, Finlay E. Screening for Lipid Disorders in Children and Adolescents. American Family Physician. 2024;110(3):261-274. https://doi.org/10.1001/jama.2023.8867
Torres-Jiménez AR, Solís-Vallejo E, Sanchez-Jara B, Cespedes-Cruz AI, Zeferino-Cruz M. Xanthomas and macrothrombocytopenia: Sitosterolaemia is the answer. Reumatol Clin. 2016;12(3):164-166. https://doi.org/10.1016/j.reuma.2015.07.001
Zodda D, Giammona R, Schifilliti S. Treatment strategy for dyslipidemia in cardiovascular disease prevention: Focus on old and new drugs. Pharmacy (Basel). 2018;6(1):10. https://doi.org/10.3390/pharmacy6010010
Liu C, Chen J, Chen H, Zhang T, He D, Luo Q, et al. PCSK9 inhibition: From current advances to evolving future. Cells. 2022;11(19):2972. https://doi.org/10.3390/cells11192972
Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 inhibition: Insights from clinical trials and future prospects. Front Physiol. 2020;11:595819. https://doi.org/10.3389/fphys.2020.595819
Parikh RR, Breve F, Magnusson P, Behzadi P, Pergolizzi J. The use of monoclonal antibody-based proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia. Cureus. 2022;14(6):e25641. https://doi.org/10.7759/cureus.25641
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341-350. https://doi.org/10.1016/S0140-6736(14)61374-X
Tromp TR, Cuchel M. New algorithms for treating homozygous familial hypercholesterolemia. Curr Opin Lipidol. 2022;33(6):326-335. https://doi.org/10.1097/MOL.0000000000000853
Vogel RA. PCSK9 inhibition: The next statin? J Am Coll Cardiol. 2012;59(25):2354-2355. https://doi.org/10.1016/j.jacc.2012.03.011
Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113-2120. https://doi.org/10.1161/CIRCULATIONAHA.113.004678
Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(6):565-574. https://doi.org/10.1016/j.jacc.2019.12.020
Santos RD, Ruzza A, Hovingh GK, Stefanutti C, Mach F, Descamps OS, et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): A single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022;10(10):732-740. https://doi.org/10.1016/S2213-8587(22)00221-2
Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: The ODYSSEY HoFH trial. J Am Coll Cardiol. 2020;76(2):131-142. https://doi.org/10.1016/j.jacc.2020.05.027
Bruckert E, Caprio S, Wiegman A, Charng MJ, Zárate-Morales CA, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: Phase 3, multinational open-label study. Arterioscler Thromb Vasc Biol. 2022;42(12):1447-1457. https://doi.org/10.1161/ATVBAHA.122.317793
Hovingh GK, Lepor NE, Kallend D, Stoekenbroek RM, Wijngaard PLJ, Raal FJ. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: The ORION-2 pilot study. Circulation. 2020;141(22):1829-1831. https://doi.org/10.1161/CIRCULATIONAHA.119.044431
Khan Z, Singh A, Haseeb Ur Rasool M, Qasim N, Yafaa Naveed Chaudhary M, Syed S, et al. Efficacy and outcomes of inclisiran in the management of homozygous and heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. Ann Med Surg (Lond). 2025;87(3):1599-1608. https://doi.org/10.1097/MS9.0000000000002982
Kohlman-Trigoboff D. Review of article: Inclisiran for the treatment of heterozygous familial hypercholesterolemia. J Vasc Nurs. 2023;41(1):38-39. https://doi.org/10.1016/j.jvn.2023.01.004
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. https://doi.org/10.1056/NEJMoa1913805
Rai R, Devi P, Kumar K, Naeem K, Kumar H, Kumari K, et al. Efficacy of inclisiran in patients having familial hypercholesterolemia: Heterozygous compared to homozygous trait, a systematic review and meta-analysis. Crit Pathw Cardiol. 2024;23(2):73-80. https://doi.org/10.1097/HPC.0000000000000353
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. https://doi.org/10.1016/j.jacc.2020.12.058
Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: Results From the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354-362. https://doi.org/10.1161/CIRCULATIONAHA.122.063460
Brown WV, Rader DJ, Goldberg AC. JCL roundtable: Drug treatment of severe forms of familial hypercholesterolemia. J Clin Lipidol. 2014;8(1):10-17. https://doi.org/10.1016/j.jacl.2013.09.004
Dixon DL, Sisson EM, Butler M, Higbea A, Muoio B, Turner B. Lomitapide and mipomersen: Novel lipid-lowering agents for the management of familial hypercholesterolemia. J Cardiovasc Nurs. 2014;29(5):E7-E12. https://doi.org/10.1097/JCN.0000000000000104
Rader DJ, Kastelein JJ. Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022-1032. https://doi.org/10.1161/CIRCULATIONAHA.113.001292
Kim SH, Baek SH. Lomitapide, relief pitcher for patients with homozygous familial hypercholesterolemia. Eur J Prev Cardiol. 2020;27(2):155-156. https://doi.org/10.1177/2047487319881240
Davis KA, Miyares MA. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Am J Health-Syst Pharm. 2014;71(12):1001-1008. https://doi.org/10.2146/ajhp130592
Perry CM. Lomitapide: A review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013;13(4):285-296. https://doi.org/10.1007/s40256-013-0030-7
Stefanutti C. Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2020;22(8):38. https://doi.org/10.1007/s11883-020-00858-4
Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40-46. https://doi.org/10.1016/S0140-6736(12)61731-0
Harada-Shiba M, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, et al. Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2017;24(4):402-411. https://doi.org/10.5551/jat.38216
Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study. J Atheroscler Thromb. 2019;26(4):368-377. https://doi.org/10.5551/jat.45708
Underberg JA, Cannon CP, Larrey D, Makris L, Blom D, Phillips H. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). J Clin Lipidol. 2020;14(6):807-817. https://doi.org/10.1016/j.jacl.2020.08.006
D'Erasmo L, Gallo A, Cefalù AB, Di Costanzo A, Saheb S, Giammanco A, et al. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): A cross-national retrospective survey. Orphanet J Rare Dis. 2021;16(1):381. https://doi.org/10.1186/s13023-021-01999-8
D'Erasmo L, Steward K, Cefalù AB, Di Costanzo A, Boersma E, Bini S, et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: The pan-European retrospective observational study. Eur J Prev Cardiol. 2022;29(5):832-841. https://doi.org/10.1093/eurjpc/zwab229
Kolovou G, Diakoumakou O, Kolovou V, Fountas E, Stratakis S, Zacharis E, et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2020;27(2):157-165. https://doi.org/10.1177/2047487319870007
Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18(12):1261-1268. https://doi.org/10.1080/14656566.2017.1340941
Brunham LR, Hegele RA. Lomitapide for the treatment of homozygous familial hypercholesterolaemia in children. Lancet Diabetes Endocrinol. 2024;12(12):866-867. https://doi.org/10.1016/S2213-8587(24)00277-8
Esba LCA, Alharbi H. Lomitapide: A medication use evaluation and a formulary perspective. Glob J Qual Saf Healthc. 2024;7(2):59-62. https://doi.org/10.36401/JQSH-23-32
Brahm AJ, Hegele RA. Lomitapide for the treatment of hypertriglyceridemia. Expert Opin Investig Drugs. 2016;25(12):1457-1463. https://doi.org/10.1080/13543784.2016.1254187
Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220-2227. https://doi.org/10.1056/NEJMoa1002926
Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054-2063. https://doi.org/10.1016/j.jacc.2017.02.030
Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211-221. https://doi.org/10.1056/NEJMoa1612790
Dingman R, Bihorel S, Gusarova V, Mendell J, Pordy R. Evinacumab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(6):e13836. https://doi.org/10.1111/cts.13836
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711-720. https://doi.org/10.1056/NEJMoa2004215
Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, et al. Evinacumab in homozygous familial hypercholesterolaemia: Long-term safety and efficacy. Eur Heart J. 2024;45(27):2422-2434. https://doi.org/10.1093/eurheartj/ehae325
Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343-353. https://doi.org/10.1161/CIRCULATIONAHA.123.065529
Toth PP. Evinacumab therapy for homozygous familial hypercholesterolemia: Driving lipoprotein clearance via the road less taken. JACC Adv. 2023;2(9):100646. https://doi.org/10.1016/j.jacadv.2023.100646
Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother. 2019;20(2):127-131. https://doi.org/10.1080/14656566.2018.1550071
Cegla J, Walji S, Barton L, Neuwirth C, Thompson GR. Treatment of homozygous familial hypercholesterolemia. JACC Adv. 2025;4(5):101708. https://doi.org/10.1016/j.jacadv.2025.101708
Fu Q, Hu L, Shen T, Yang R, Jiang L. Recent advances in gene therapy for familial hypercholesterolemia: An update review. J Clin Med. 2022;11(22):6773. https://doi.org/10.3390/jcm11226773
Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: The LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272-4280. https://doi.org/10.1093/eurheartj/ehad596
Raal FJ, Mehta V, Kayikcioglu M, Blom D, Gupta P, Elis A, et al. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): A phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025;13(3):178-187. https://doi.org/10.1016/S2213-8587(24)00313-9
Gianos E, Duell PB, Toth PP, Moriarty PM, Thompson GR, Brinton EA, et al. Lipoprotein apheresis: Utility, outcomes, and implementation in clinical practice: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2024;44(12):e304-e321. https://doi.org/10.1161/ATV.0000000000000177
Zhan HS, Wei L, Qu W, Zeng ZG, Liu Y, Tan YL, et al. Liver transplantation for homozygous familial hypercholesterolemia: A retrospective analysis from Chinese experience. Orphanet J Rare Dis. 2025;20(1):26. https://doi.org/10.1186/s13023-024-03443-z
Al Dubayee M, Kayikcioglu M, van Lennep JR, Hergli N, Mata P. Is liver transplant curative in homozygous familial hypercholesterolemia? a review of nine global cases. Adv Ther. 2022;39(6):3042-3057. https://doi.org/10.1007/s12325-022-02131-3
Bajaj A, Cuchel M. Homozygous familial hypercholesterolemia: What treatments are on the horizon? Curr Opin Lipidol. 2020;31(3):119-124. https://doi.org/10.1097/MOL.0000000000000677
de Ferranti SD. Familial hypercholesterolemia in children and adolescents: A clinical perspective. J Clin Lipidol. 2015;9(5 Suppl):S11-19. https://doi.org/10.1016/j.jacl.2015.04.009
de Ferranti SD, Shrader P, Linton MF, Knowles JW, Hudgins LC, Benuck I, et al. Children with heterozygous familial hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. J Pediatr. 2021;229:70-77. https://doi.org/10.1016/j.jpeds.2020.09.042
de Ferranti SD, Kazi DS, Bibbins-Domingo K, Daniels S, Howaniec B, Khera AV, et al. Perspectives on identifying and treating familial hypercholesterolemia in childhood. Clin Chem. 2021;67(10):1312-1317. https://doi.org/10.1093/clinchem/hvab157
Raal FJ, Hegele RA, Ruzza A, López JAG, Bhatia AK, Wu J, et al. Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: Pooled data from three open-label studies. Arterioscler Thromb Vasc Biol. 2024;44(5):1156-1164. https://doi.org/10.1161/ATVBAHA.123.320268
Das T, Mondal S, Rawool AK, Tarafdar S, Ghosh A. Importance of genotype-phenotype correlation in the population screening of familial hypercholesterolemia. Cureus. 2025;17(2):e79252. https://doi.org/10.7759/cureus.79252
Gidding SS, Blom DJ, McCrindle B, Ramaswami U, Santos RD, Watts GF, et al. Life course approach for managing familial hypercholesterolemia. J Am Heart Assoc. 2025;14(7):e038458. https://doi.org/10.1161/JAHA.124.038458
Gu J, Ma X, Park J, Li Y, Sanchez RJ. High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: A real-world study. J Clin Lipidol. 2025;19(2):303-309. https://doi.org/10.1016/j.jacl.2024.11.004
Al-Ashwal A, Al-Mansour S, Al-Shagrani M, Al-Gofi T, Broering D, Alhuthil R. The effectiveness of liver transplantation in reducing lipid levels in Saudi children with homozygous familial hypercholesterolemia. Front Cardiovasc Med. 2024;11:1454638. https://doi.org/10.3389/fcvm.2024.1454638
Lin D, Lu Y, Qiu B, Feng M, Luo Y, Xue F, et al. The therapeutic effect of liver transplantation in 14 children with homozygous familial hypercholesterolemia: A prospective cohort: Liver transplant for familial hypercholesterolemia. J Clin Lipidol. 2024;18(6):e1055-e1066. https://doi.org/10.1016/j.jacl.2024.08.008
Y?lmaz Da?l? H, Artan R, Civan DD, ?nan Aydemir N, Y?lmaz A. Is liver transplantation alone an effective treatment for homozygotic familial hypercholesterolemia in children? Pediatr Transplant. 2024;28(7):e14853. https://doi.org/10.1111/petr.14853
Golbus JR, Farhat L, Fontana RJ, Rubenfire M. Rapidly progressive atherosclerosis after domino liver transplantation from a teenage donor with homozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(5):1284-1288. https://doi.org/10.1016/j.jacl.2017.07.006
Greco M, Robinson JD, Eltayeb O, Benuck I. Progressive aortic stenosis in homozygous familial hypercholesterolemia after liver transplant. Pediatrics. 2016;138(5):e20160740. https://doi.org/10.1542/peds.2016-0740
Ben-Omran T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, et al. Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786-1811. https://doi.org/10.1007/s12325-019-00985-8
Masana L, Zambon A, Schmitt CP, Taylan C, Driemeyer J, Cohen H, et al. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): Results from the efficacy phase of an open-label, multicentre, phase 3 study. Lancet Diabetes Endocrinol. 2024;12(12):880-889. https://doi.org/10.1016/S2213-8587(24)00233-X
Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis. 2006;189(2):451-457. https://doi.org/10.1016/j.atherosclerosis.2006.01.002
Kaur G, Gulati M. Considerations for treatment of lipid disorders during pregnancy and breastfeeding. Prog Cardiovasc Dis. 2022;75:33-39. https://doi.org/10.1016/j.pcad.2022.11.001
Blaha M, Lanska M, Blaha V, Boudys L, Zak P. Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis. Atheroscler Suppl. 2015;18:134-139. https://doi.org/10.1016/j.atherosclerosissup.2015.02.024
Ogura M, Makino H, Kamiya C, Yoshimatsu J, Soran H, Eatough R, et al. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis. 2016;254:179-183. https://doi.org/10.1016/j.atherosclerosis.2016.10.018
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Revista Colombiana de Endocrinología, Diabetes & Metabolismo